PE
BMRN icon

Point72 Europe’s BioMarin Pharmaceuticals BMRN Stock Holding History

Point72 Europe’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,580
Closed -$3.86M – 165
2025
Q1 		$3.86M Sell
54,580
-6,161
-10% -$414K 0.26% 95
2024
Q4 		$3.99M Buy
+60,741
New +$4.07M 0.23% 87

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Europe's BMRN Position: Q2 2025 in Review

Point72 Europe sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 54,580 shares — an estimated $3.86M sold.

Point72 Europe first reported a position in BMRN in Q4 2024 and held it in 2 quarters. The position peaked at $3.99M in Q4 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Point72 Europe reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Europe sold 54,580 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $3.86M.
  • Point72 Europe first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Point72 Europe's BioMarin Pharmaceuticals position peaked at $3.99M in Q4 2024.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Point72 Europe's 13F filing for Q2 2025, filed 14 Aug 2025.